Accessibility Menu
Vectus Biosystems logo

Vectus Biosystems(ASX) VBS

Market CapA$10.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-89%
5 Year-89%
1 Year+126%
1 Month+3%
A$0.17
-10.81%
-0.02Today
Vectus Biosystems last closing stock price
MetricPriceDate
Last closeAUD 0.172026-09-07
Vectus Biosystems stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.81%AUD 0.192026-08-31
1 month+3.13%AUD 0.162026-08-06
3 month+32%AUD 0.132026-06-05
Year to date-8.33%AUD 0.182025-12-31
1 year+126.03%AUD 0.072025-09-04
3 year-58.75%AUD 0.402023-09-07
5 year-89%AUD 1.502021-09-08
Since inception-89.35%AUD 1.552016-02-23

Vectus Biosystems Financials at a Glance

Market Cap

A$10.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$478.18K

Net Income (TTM)

-A$218.61K

EPS (TTM)

A$0.03

P/E Ratio

5.73

Dividend

A$0.00

Beta (Volatility)

-0.32 (Low)

Price

A$0.17

Volume

0

Open

A$0.19

Previous Close

A$0.17

Daily Range

A$0.17 - A$0.19

52-Week Range

A$0.05 - A$0.46

Estimated Earnings Date

Feb 19, 2026

VBS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vectus Biosystems

Vectus Biosystems Limited is an Australian biotechnology firm focused on developing innovative therapies for fibrotic conditions and hypertension. The company’s pharmaceutical pipeline targets critical ailments affecting vital organs, including the heart, kidneys, liver, and lungs.

Products and Services
  • VB0004: An experimental drug aimed at combating tissue degradation from fibrosis
  • AccuCal: Software designed for precise DNA and RNA quantification
  • RealCount: A tool to enhance laboratory efficiency in quantification processes
Growth Outlook
  • Strong focus on advancing treatments for hepatic fibrotic diseases
  • Potential market expansion in pulmonary fibrotic disorders
  • Continued investment in R&D to drive innovation and product development
Financial Highlights
  • Recent quarterly revenue of 0, indicating ongoing development phase
  • Trailing twelve months (TTM) net income margin of -16.68%, reflecting investment in growth
  • Cash and cash equivalents of AUD 330,496 as of the latest quarter
Vectus Biosystems Limited is positioned in a niche market with significant growth potential, particularly in the treatment of fibrotic diseases. The company’s leading drug, VB0004, represents a promising advancement in addressing the challenges posed by fibrosis. The ongoing development of AccuCal and RealCount software further enhances the company’s portfolio, providing valuable tools for laboratory settings. Despite recent financial challenges, including a TTM net income margin of -16.68%, the company continues to invest heavily in research and development. This commitment to innovation is crucial for long-term growth and market competitiveness. The current cash position of AUD 330,496 provides a foundation for continued operations and development efforts. Overall, Vectus Biosystems Limited presents an intriguing opportunity for investors interested in the biotechnology sector, particularly those focused on innovative therapies for complex medical conditions.
AI Generated • Aug 26, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Tara Speranza

Website

www.vectusbiosystems.com.au

Headquarters

Rosebery, NSW 2018, AU

VBS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

206.11%

Return on Capital

-47.76%

Return on Assets

40.82%

Earnings Yield

17.45%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$10.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

62.18M

Volume

0

Avg. Volume

23.31K

Financials (TTM)

Gross Profit

A$473.59K

Operating Income

-A$3.06M

EBITDA

-A$3.05M

Operating Cash Flow

-A$1.40M

Capital Expenditure

A$3.00

Free Cash Flow

-A$1.40M

Cash & ST Invst.

A$3.52M

Total Debt

A$546.67K

Vectus Biosystems Performance Analysis

Vectus Biosystems annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Vectus Biosystems sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-19.7%
Q42025-06-30-78.5%
Q22025-12-31-100.0%
Q42026-06-30N/A
Vectus Biosystems annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.07-40.0%
20242024-06-30AUD -0.04-38.7%
20252025-06-30AUD -0.04-20.5%
20262026-06-30AUD 0.03N/A
Vectus Biosystems sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-315.0%
Q42025-06-3038.6%
Q22025-12-31-7.9%
Q42026-06-30405.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$3.01K

-100.6%

Gross Margin

0.00%

N/A

Market Cap

A$10.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.05M

N/A

Employees

5

N/A

Net Income

A$2.29M

+297.5%

EBITDA

-A$649.76K

+42.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$3.52M

+334.7%

Total Debt

A$546.67K

+1789.9%

Accounts Receivable

A$224.87K

-77.0%

Inventory

A$0.00

-100.0%

Long Term Debt

A$494.78K

N/A

Short Term Debt

A$51.88K

+79.4%

Return on Assets

40.82%

N/A

Return on Invested Capital

-48.64%

N/A

Free Cash Flow

-A$402.90K

+67.5%

Operating Cash Flow

-A$402.90K

+68.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IXC.AXInvex Therapeutics Ltd
A$0.12+0.00%
ACR.AXAcrux Limited
A$0.01+0.00%
HIQ.AXHITIQ Limited
A$0.01+20.00%
BGT.AXBio-Gene Technology Limited
A$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$100.83+0.05%
NVDANvidia
$228.85-0.01%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$44.27-0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.48+0.04%

Questions About VBS

What is the current price of Vectus Biosystems?

Vectus Biosystems is trading at A$0.17 per share.

What is the 52-week range for Vectus Biosystems?

Over the past 52 weeks, Vectus Biosystems has traded between A$0.05 and A$0.46.

How much debt does Vectus Biosystems have?

As of the most recent reporting period, Vectus Biosystems reported total debt of A$546.67K.

How much cash does Vectus Biosystems have on hand?

Vectus Biosystems reported A$718.59K in cash and cash equivalents in its most recent financial results.

What is Vectus Biosystems’s dividend yield?

Vectus Biosystems does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services